Tel:
Fax:
Email:
Creative Biolabs

NeuroMab™ Anti-Tau Antibody(NRP-0422-P1708)

[CAT#: NRP-0422-P1708]

Functional antibody against Human Tau

Host Species:
Mouse
Species Reactivity:
Human
Applications:
WB; IHC; In Vitro; In Vivo

Datasheet MSDS Request COA

Certificate of Analysis Lookup
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number

Inquiry

SPECIFIC INQUIRY

inquiry
Size:
Conjugation:
Endotoxin:
Purity:
Engineering:
Product Overview

Description

The anti-Tau antibody specifically recognize and bind to phosphorylated pathological protein tau-conformers in brain sections from AD and tauopathy patients (TAUPIR).

Species Reactivity

Human

Clonality

Monoclonal

Host Species

Mouse

Applications

WB; IHC; In Vitro; In Vivo

Application Notes

EGFR

Relevant Diseases

Alzheimer's Disease
Product Properties

Formulation

PBS only

Preservatives

BSA Free

Concentration

1mg/mL

Purification

Purified recombinant IgG prepared by affinity chromatography on Protein A from a mammalian cell line

Purity

> 95% (SDS-PAGE)

Endotoxin Level

Regular Endotoxin < 5 EU/mg
Low Endotoxin < 1 EU/mg

Shipping

Gel Packs

Storage

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Research Use Only

For research use only
Target

Target

Tau

Official Name

Tau

Full Name

Tau

Alternative Names

CD14

Gene ID

4137(Human); 17762(Mouse); 29477(Rat)

Uniprot ID

P10636(Human); P10637(Mouse); P19332(Rat)
Product Pictures
IHC

Figure 1 shows antibody binding to phosphorylated Tau in AD and tau disease patient brain slices using the ACI-36-3A8-Ab1 antibody using TAUPIR.

FuncS

Figure 10 shows IHC following anti-Tau antibody treatment with ACI-36-2B6-Ab1 in a 3-month in vivo study.

FuncS

Figure 11 shows the Morris water maze results after ACI-36-2B6-Ab1 anti-Tau antibody treatment in a 3-month in vivo study.

FuncS

Figure 12 shows the Morris water maze results after ACI-36-3A8-AM anti-Tau antibody treatment in a 3-month in vivo study.

FuncS

Figure 2 shows the effect of anti-Tau antibody treatment after a 1-week in vivo study of the pTau epitope pT231 using MSD.

FuncS

Figure 3 shows the effect of anti-Tau antibody treatment after a 1-week in vivo study of the pTau epitope pT231 using MSD.

WB

Figure 4 shows the pTau epitope western blot after anti-Tau antibody treatment in a 1-month in vivo study.

WB

Figure 5 shows pTau epitope western blot results after anti-Tau antibody treatment in a 3-month in vivo study.

WB

Figure 6 shows the pTau epitope western blot after anti-Tau antibody treatment for a 3-month in vivo study using biGT biomouse.

WB

Figure 7 shows pTau epitope Western blot results after anti-Tau antibody treatment for a 3-month in vivo study using biGT biomouse.

WB

Figure 8 shows pTau epitope western blot results after anti-Tau antibody treatment for a 3-month in vivo study using biGT biomouse.

FuncS

Figure 9 shows IHC after anti-Tau antibody treatment by ACI-36-2B6-Ab1 in a 3-month in vivo study.

Publications

Publications (0)

gift-card

Related Products
Kits
Neural Antibodies
Neural Genes
Neural Cell Lines
For Research Use Only. Not For Clinical Use.
Product
Hot Products
Fill out this form for a quote Inquiry Form Send Inquiry
webinar

The Spectrum of Stem Cell-Based Neuronal Models and Their Fit for Purpose

2:00 PM–3:00 PM EST, December 12, 2024

REGISTER NOW
Inquiry Basket
compare

Send inquiry